Antitumor effect of regorafenib on microRNA expression in hepatocellular carcinoma cell lines

Persistent ID (NDL): info:ndljp/pid/12314245

Material type: 博士論文

Author: 琢磨, 慧

Publisher: -

Publication date: 2022-06-29

Material Format: Digital

Capacity, size, etc.: -

Name of awarding university/degree: 香川大学,博士（医学）

View All

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある学位授与機関のWebサイトやCiNii Dissertationsから、本文を自由に閲覧できる場合があります。

Notes on use

Note (General)：: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is one of the leading causes of cancer-related deaths worldwide....

Search by Bookstore

Read this material in an accessible format.

View materials in accessible formats for people with print disabilities (1Type)

Search by Bookstore

Read in Disability Resources

Other Services
- テキストデータ check it on 国立国会図書館デジタルコレクション

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type: 博士論文
Title: Antitumor effect of regorafenib on microRNA expression in hepatocellular carcinoma cell lines
Author/Editor: 琢磨, 慧
Author Heading: 琢磨, 慧
Publication Date: 2022-06-29
Publication Date (W3CDTF): 2022-06-29
Alternative Title: 肝細胞癌におけるMicroRNAに対するレゴラフェニブの抗腫瘍効果の検討
Degree grantor/type: 香川大学
Date Granted: 2022-06-29
Date Granted (W3CDTF): 2022-06-29
Dissertation Number: 甲第813号
Degree Type: 博士（医学）
Conferring No. (Dissertation): 甲第813号
Text Language Code: eng
Alias of Author: Takuma, Kei
Subject Heading: hepatocellular carcinoma
regorafenib
cell cycle
cell proliferation
cyclin
microRNA
antitumor effect
Target Audience: 一般
Note (General): Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is one of the leading causes of cancer-related deaths worldwide. Regorafenib, a multi-kinase inhibitor, is used as a second-line treatment for advanced HCC. Here, we aimed to investigate the mechanism of the antitumor effect of regorafenib on HCC and evaluate altered microRNA (miRNA) expression. Cell proliferation was examined in six HCC cell lines (HuH-7, HepG2, HLF, PLC/PRF/5, Hep3B, and Li-7) using the Cell Counting Kit-8 assay. Xenografted mouse models were used to assess the effects of regorafenib in vivo. Cell cycle analysis, western blotting analysis, and miRNA expression analysis were performed to identify the antitumor inhibitory potential of regorafenib on HCC cells. Regorafenib suppressed proliferation in HuH-7 cell and induced G0/G1 cell cycle arrest and cyclin D1 downregulation in regorafenib-sensitive cells. During miRNA analysis, miRNA molecules associated with the antitumor effect of regorafenib were found. Regorafenib suppresses cell proliferation and tumor growth in HCC by decreasing cyclin D1 via alterations in intracellular and exosomal miRNAs in HCC.
DOI: info:doi/10.3390/ijms23031667
https://doi.org/info:doi/10.3390/ijms23031667
Persistent ID (NDL): info:ndljp/pid/12314245
https://dl.ndl.go.jp/pid/12314245
Collection: 障害者向け資料
Collection (Materials For Handicapped People:1): テキストデータ
Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
https://dl.ndl.go.jp/collections/A00014
Acquisition Basis: 博士論文（自動収集）
Date Accepted (W3CDTF): 2022-08-08T06:02:54+09:00
Date Created (W3CDTF): 2022-07-07
Format (IMT): PDF
Access Restrictions: 国立国会図書館内限定公開
Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
Availability of remote photoduplication service: 可
Periodical Title (URI): https://kagawa-u.repo.nii.ac.jp/records/9801
Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション
https://dl.ndl.go.jp